FDA
-
-
-
-
-
-
-
Lisata Therapeutics' (LSTA) Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
-
-
-
-
-
-
-
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
-
-
-
-
-
-
-
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

